Arcus Biosciences | 10-Q: Quarterly report
Arcus Biosciences 1Q Rev $145M >RCUS
Arcus Biosciences 1Q Rev $145M >RCUS
Earnings Flash (RCUS) ARCUS BIOSCIENCES Posts Q1 Revenue $145M
04:03 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (RCUS) ARCUS BIOSCIENCES Posts Q1 Revenue $145M
Arcus Biosciences 1Q Loss $4M >RCUS
Arcus Biosciences 1Q Loss $4M >RCUS
Arcus Biosciences 1Q Loss/Shr 5c >RCUS
Arcus Biosciences 1Q Loss/Shr 5c >RCUS
Press Release: Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update
Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update -- Arcus data will be disclosed in two oral presentations at the 2024 American Society of Clini
Will Arcus Biosciences, Inc. (RCUS) Report Negative Earnings Next Week? What You Should Know
Analysts Offer Insights on Healthcare Companies: Daré Bioscience (DARE), Mereo Biopharma Group Plc (MREO) and Arcus Biosciences (RCUS)
Promising Outlook for Arcus Biosciences Anchored by Strong Clinical Trials and Strategic Market Positioning
Arcus Biosciences to Present New Data From Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
Updated data from EDGE-Gastric evaluating domvanalimab plus zimberelimab and chemotherapy in upper gastrointestinal (GI) cancers will be presented in a special ASCO plenary series rapid abstract update session by
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Arcus Biosciences (RCUS)
Exelixis Slips as Barclays Downgrades on Lack of Catalysts
Top Buy-rated Stocks and Sell-rated Stocks Within Health Care - Citi
Investors Bid Arcus Biosciences (NYSE:RCUS) up US$219m Despite Increasing Losses YoY, Taking Five-year CAGR to 8.1%
Insider Sell: COO Jennifer Jarrett Sells 11,551 Shares of Arcus Biosciences Inc (RCUS)
Arcus Biosciences(RCUS.US) Officer Sells US$202.72K in Common Stock
$Arcus Biosciences(RCUS.US)$ Officer Jarrett Jennifer sold 11,551 shares of Common Stock on Mar 27, 2024 at an average price of $17.55 for a total value of $202.72K.Source: Announcement What is statem
Arcus Biosciences Grants Four New Employees Options to Purchase Total of 18,400 Shrs >RCUS
Arcus Biosciences Grants Four New Employees Options to Purchase Total of 18,400 Shrs >RCUS
Truist Securities Reiterates Buy on Arcus Biosciences, Maintains $50 Price Target
Truist Securities analyst Robyn Karnauskas reiterates Arcus Biosciences (NYSE:RCUS) with a Buy and maintains $50 price target.
Arcus Biosciences Chief Operating Officer Jennifer Jarrett Sells 27% Of Holding
We'd be surprised if Arcus Biosciences, Inc. (NYSE:RCUS) shareholders haven't noticed that the Chief Operating Officer, Jennifer Jarrett, recently sold US$241k worth of stock at US$17.92 per share.
No Data